Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab + tislelizumab versus pembrolizumab in first-line PD-L1-high advanced non-small cell lung cancer
NL-OMON56010Phase 3Recruiting
- Sponsor
- BeiGene
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ociperlimab + tislelizumab, Pembrolizumab + placebo and Tislelizumab + placebo (3 arms). Primary endpoints: Progression-free survival by investigator and Overall survival. Started May 2022; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56010.